Biofrontera to Present at Lytham Partners Fall 2025 Investor Conference
ByAinvest
Friday, Sep 26, 2025 9:17 am ET1min read
BFRI--
The webcast presentation will be held at 1:15 p.m. ET on September 30, 2025. Investors can access the webcast through the conference home page at [https://lythampartners.com/fall2025/](https://lythampartners.com/fall2025/) or directly at [https://app.webinar.net/wWqPp4Yr0kD](https://app.webinar.net/wWqPp4Yr0kD). The webcast will also be available for replay following the event.
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at [https://lythampartners.com/fall2025invreg/](https://lythampartners.com/fall2025invreg/).
Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on the development and treatment of dermatological conditions, with a particular emphasis on photodynamic therapy (PDT). The company commercializes the drug-device combination Ameluz ® with the RhodoLED ® lamp series for PDT of actinic keratosis (AK) and pre-cancerous skin lesions, which may progress to invasive skin cancers. Biofrontera is also conducting clinical trials to extend the use of its products to treat non-melanoma skin cancers and moderate to severe acne.
For more information, visit [www.biofrontera-us.com](http://www.biofrontera-us.com) and follow Biofrontera on LinkedIn and X.
Biofrontera Inc. will participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025. The company will have a webcast presentation and host one-on-one meetings with investors. The webcast can be accessed through the conference home page or directly at https://app.webinar.net/wWqPp4Yr0kD. Biofrontera is a biopharmaceutical company specializing in dermatological products, including Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions.
Biofrontera Inc. (NASDAQ: BFRI), a biopharmaceutical company specializing in dermatological products, has announced its participation in the upcoming Lytham Partners Fall 2025 Investor Conference on September 30, 2025. The company will deliver a webcast presentation at 1:15 p.m. ET and conduct one-on-one meetings with investors throughout the virtual event.The webcast presentation will be held at 1:15 p.m. ET on September 30, 2025. Investors can access the webcast through the conference home page at [https://lythampartners.com/fall2025/](https://lythampartners.com/fall2025/) or directly at [https://app.webinar.net/wWqPp4Yr0kD](https://app.webinar.net/wWqPp4Yr0kD). The webcast will also be available for replay following the event.
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at [https://lythampartners.com/fall2025invreg/](https://lythampartners.com/fall2025invreg/).
Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on the development and treatment of dermatological conditions, with a particular emphasis on photodynamic therapy (PDT). The company commercializes the drug-device combination Ameluz ® with the RhodoLED ® lamp series for PDT of actinic keratosis (AK) and pre-cancerous skin lesions, which may progress to invasive skin cancers. Biofrontera is also conducting clinical trials to extend the use of its products to treat non-melanoma skin cancers and moderate to severe acne.
For more information, visit [www.biofrontera-us.com](http://www.biofrontera-us.com) and follow Biofrontera on LinkedIn and X.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet